WO2020132774A1 - Anticuerpo monoclonal o una porción de unión a antígeno del mismo que se une a la proteína l del virus parainfluenza humano (piv); método y kit para detectar al virus piv - Google Patents
Anticuerpo monoclonal o una porción de unión a antígeno del mismo que se une a la proteína l del virus parainfluenza humano (piv); método y kit para detectar al virus piv Download PDFInfo
- Publication number
- WO2020132774A1 WO2020132774A1 PCT/CL2019/050157 CL2019050157W WO2020132774A1 WO 2020132774 A1 WO2020132774 A1 WO 2020132774A1 CL 2019050157 W CL2019050157 W CL 2019050157W WO 2020132774 A1 WO2020132774 A1 WO 2020132774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piv
- antibody
- detection
- seq
- cdr
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 29
- 208000002606 Paramyxoviridae Infections Diseases 0.000 title claims abstract description 21
- 239000000427 antigen Substances 0.000 title claims description 58
- 102000036639 antigens Human genes 0.000 title claims description 58
- 108091007433 antigens Proteins 0.000 title claims description 58
- 102000004169 proteins and genes Human genes 0.000 title claims description 31
- 108090000623 proteins and genes Proteins 0.000 title claims description 31
- 230000027455 binding Effects 0.000 title claims description 17
- 239000012634 fragment Substances 0.000 title abstract description 25
- 239000012472 biological sample Substances 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims description 80
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 51
- 238000002965 ELISA Methods 0.000 claims description 35
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 34
- 238000003556 assay Methods 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000000523 sample Substances 0.000 claims description 23
- 229960002685 biotin Drugs 0.000 claims description 17
- 235000020958 biotin Nutrition 0.000 claims description 17
- 239000011616 biotin Substances 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000010166 immunofluorescence Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- -1 radioisotopes Substances 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 238000001114 immunoprecipitation Methods 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 150000002739 metals Chemical class 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000003317 immunochromatography Methods 0.000 claims description 2
- 230000000951 immunodiffusion Effects 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims 1
- 239000004677 Nylon Substances 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229920001220 nitrocellulos Polymers 0.000 claims 1
- 229920001778 nylon Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 abstract description 22
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 4
- 210000004408 hybridoma Anatomy 0.000 description 50
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 29
- 239000002953 phosphate buffered saline Substances 0.000 description 29
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 15
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000004005 microsphere Substances 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 11
- 229920001213 Polysorbate 20 Polymers 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- 230000000241 respiratory effect Effects 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000012286 ELISA Assay Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 6
- 238000003118 sandwich ELISA Methods 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 101710102873 Polymerase basic protein 2 Proteins 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 238000003759 clinical diagnosis Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000012304 luminex technique Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 240000005702 Galium aparine Species 0.000 description 3
- 235000014820 Galium aparine Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 2
- 241000726041 Human respirovirus 1 Species 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- 241001559187 Human rubulavirus 2 Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 201000010549 croup Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000009589 serological test Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241001559186 Human rubulavirus 4 Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000014155 detection of activity Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 101150020161 flu-2 gene Proteins 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 108700015453 influenza virus PB2 Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Definitions
- Monoclonal antibodies, or fragments thereof, are presented that recognize the human parainfluenza virus (PIV) chimera L protein, where said monoclonal antibodies or fragments thereof comprise a variable light chain region where their CDR1 (CDR LCI ) is defined by SEQ ID NO: 1, your CDR2 (CDR LC2 ) is defined by SEQ ID NO: 2, and your CDR3 (CDR LC3 ) corresponds to SEQ ID NO: 3, and a variable region of the heavy chain where your CDR1 ( CDR HCI ) is defined according to SEQ ID NO: 4, its CDR2 (CDR HC 2) corresponds to SEQ ID NO:
- CDR HC3 corresponds to SEQ ID NO: 6
- a light chain variable region where your CDR1 (CDR LCI ) is defined according to SEQ ID NO: 7, your CDR2 (CDR LC2 ) is defined by SEQ ID NO: 8 and its CDR3 (CDR LC3 ) corresponds to SEQ ID NO: 9, and a variable region of the heavy chain where its CDR1 (CDR HCI ) is defined according to SEQ ID NO: 10, its CDR2 (CDR HC2 ) corresponds to SEQ ID NO: 11 and its CDR3 (CDR HCS ) corresponds to SEQ ID NO: 12.
- said antibodies can be used as detection and / or capture antibodies.
- a method of diagnosing PIV infection in a biological sample using monoclonal antibodies is also provided, and a diagnostic kit for detecting PIV, comprising at least one monoclonal antibody against PIV as previously described.
- the human parainfluenza virus produces an infectious disease of the upper respiratory tract that manifests itself in various clinical pictures ranging from a common cold, even pneumonia.
- Laryngotracheobronchitis is the most frequent and serious clinical manifestation.
- This disease is caused by a virus of the paramyxovirus type and is easily transmitted from person to person or through drops or small particles that have been expelled through the cough or sneeze of a sick person, which makes its spread fast and be part of seasonal epidemics.
- IVP In the United States, IVP is one of the main causes of hospitalization for respiratory diseases in young children, occurring in between 2 and 17% of cases, which translates into 250,000 visits to emergency rooms and 700,000 hospitalizations. Among children under 5, 1.2 children are hospitalized for this cause annually, this rate being higher in children under 6 months 1 .
- PIV has a more variable impact with respect to the other respiratory viruses, being responsible for 3 to 10% of hospitalizations with symptoms of bronchiolitis, pneumonia and laryngotracheobronchitis.
- RSV respiratory syncytial virus
- PIV infection reaches its peak between 4 and 12 years of age 2 .
- Infection caused by PIV can be diagnosed using direct detection methods, that is, by detecting antibodies directly in the sample or by serological tests that allow the presence of IgM antibody to be measured or the increase in IgG titers.
- Cell line assays are also used for the isolation of PIV in the clinical laboratory.
- PCR polymerase chain reaction
- Document US6015664A presents a method to determine the presence or absence of multiple viral infections in a biological sample by means of a multiplex PCR assay. The method includes nucleotide cleavers along with probes for detection of complementary nucleic acid sequences of human parainfluenza virus 1, 2, and 3, respiratory syncytial virus A and B, and influenza virus, A and B.
- RT-PCR kit for detecting parainfluenza virus in one step is disclosed in CN102140550A, where the kit includes specific primers for parainfluenza virus. TO.
- document CN105441589A describes a detection kit for parainfluenza virus type 1, 2, 3 and 4, using quadruple PCR.
- the quadruple PCR detection kit includes primers and genetic probes specific for human parainfluenza virus.
- kits based on immunofluorescence for the detection of various respiratory viruses, including parainfluenza include parainfluenza.
- the D3 Ultra DFA (direct fluorescent antibody) kit allows the qualitative identification of various respiratory viruses: influenza A, influenza B, respiratory syncytial virus, adenovirus, parainfluenza 1, parainfluenza 2 and parainfluenza 3.
- the present invention relates to specific monoclonal antibodies against the L chimera protein or fragments thereof, of the human parainfluenza virus, hereinafter PIV.
- the invention corresponds to monoclonal antibodies, or fragments thereof, that recognize the L chimera protein of human parainfluenza virus (PIV) secreted by the 2E11B5 and 4D8C6 hybridomas, where said monoclonal antibodies or fragments of these comprise a variable region light chain where your CDR1 (CDR LCI ) is defined according to SEQ ID NO: 1, your CDR2 (CDR LC2 ) is defined by SEQ ID NO: 2 and your CDR3 (CDR LCS ) corresponds to SEQ ID NO: 3 , and a variable region of the heavy chain where your CDR1 (CDR HCI ) is defined according to SEQ ID NO: 4, your CDR2 (CDR HC2 ) corresponds to SEQ ID NO: 5 and your CDR3 (CDR HCS ) corresponds to SEQ ID NO
- Said antibodies can be used as detection and / or capture antibodies.
- a method of diagnosing PIV infection in a biological sample using monoclonal antibodies is also provided, and a diagnostic kit for detecting PIV, comprising at least one monoclonal antibody against PIV as previously described.
- the antibodies recognize a chimera protein, particularly the L chimera protein of the human parainfluenza virus.
- the antibodies that are part of the scope of the invention allow specific detection of protein L or fragments thereof, so that they do not compete with each other for the antigen binding site, nor do they impede their simultaneous binding to East. Additionally, they allow detecting protein L or fragments of it with high sensitivity in samples that contain a low amount of antigen.
- the proposed monoclonal antibodies are capable of detecting protein L, a conserved protein.
- the detection strategy of a conserved viral protein allows the antibodies that are part of the scope of the invention to detect different types of the human parainfluenza virus, among them, parainfluenza 1, 2, 3 and 4.
- CDR sequences When CDR sequences are referred to in the present invention, they correspond to short sequences that are found in the variable domains of proteins that have antigen detection function.
- the CDR sequences for the heavy chain (CDR HC ) and light chain (CDRi, c) of the antibodies secreted by the 2E11B5 and 4D8C6 hybridomas are presented.
- the described monoclonal antibodies can be used for detection, diagnosis and / or determination of PIV infection. These antibodies can be used simultaneously to increase detection sensitivity in clinical samples where there is little quantity and availability of antigen.
- a method of diagnosing PIV infection in a biological sample which comprises contacting the biological sample with the monoclonal antibody against PIV L protein or a fragment thereof according to claim, and detect binding of the antibody to the antigen.
- the biological sample can correspond, without limitation, to in vitro cells infected with PIV, nasal secretions, nasal lavages, cerebrospinal fluid, pharyngeal secretions and / or lavages or bronchial secretions.
- the assay used for detection of antigen-antibody binding is selected from ELISA, luminex, immunofluorescence, immunohistochemistry, immunochromatography, flow cytometry, cell sorter, immunoprecipitation and / or Western blot.
- the present invention also includes a diagnostic kit for detecting human influenza virus, which comprises: a monoclonal antibody against PIV L protein or a fragment thereof, where said antibody can act as a capture or detection antibody , where particularly, the detection antibody is conjugated to a marker for detection; a solid support to which the antibody is attached; and reagents for detecting the marker included in the detection antibody, such as fluorophores, biotin, radioisotopes, metals, and enzymes.
- a diagnostic kit for detecting human influenza virus which comprises: a monoclonal antibody against PIV L protein or a fragment thereof, where said antibody can act as a capture or detection antibody , where particularly, the detection antibody is conjugated to a marker for detection; a solid support to which the antibody is attached; and reagents for detecting the marker included in the detection antibody, such as fluorophores, biotin, radioisotopes, metals, and enzymes.
- capture antibody when referring to capture antibody, this corresponds to the antibody that specifically binds to the antigen.
- detection antibody this corresponds to the antibody to which a marker is conjugated to be detected by different tests such as immunochromatographic test, luminex, flow cytometry, immunofluorescence, radioimmunoassay, Western blot, Dot plot, ELISA, luminex, immunodiffusion. or immunoprecipitation.
- the antibodies part of the present invention can dual function as a capture antibody or as a detection antibody when coupled to the detection marker.
- the detection marker will be conjugated to the detection antibody, and this can correspond, without limitation, to fluorophores, biotin, radioisotopes, metals and enzymes.
- the detection antibody is conjugated to the reporter system based on detection of activity of horseradish peroxidase enzyme (HRP).
- HRP horseradish peroxidase enzyme
- Figure 1 Detection of PIV chimera L protein by monoclonal antibodies produced by hybridomas 2E11B5 and 4D8C6, by means of an indirect ELISA assay.
- the plate was activated with 50 ng of purified recombinant PIV L protein, 50 ng of Flu PB2 protein (as a specificity control) and 20 pg of E. col ⁇ strain BL21 bacterial used without plasmid (used as a specificity control) and 3 clones (Cl, C2 and C3) of the same strain, in which protein L was over-expressed.
- the data shown in the graph expresses the absorbance detected at 450 nm, emitted by the conversion of the substrate Tetramethylbenzidine to a colored compound, catalyzed by the enzyme Horseradish peroxidase (HRP) present in a secondary anti-mouse IgG antibody that specifically bound to the antibodies secreted by the 2F11B1 and 4D8C6 hybridomas. Values correspond to the average +/- standard deviation of absorbance emitted by each sample in at least two independent experiments.
- the letters ns means that no significant difference is observed.
- Figure 2 Determination of sensitivity of monoclonal antibodies produced by hybridomas 2E11B5 and 4D8C6 in the detection of L protein of PIV.
- ELISA plates were activated with 1: 2 serial dilutions, starting with 50 ng of L protein and ending with 0.04 ng. Subsequently, the wells were incubated with anti-L antibodies from the 2E11B5 hybridoma, in the amount of 170 ng (A) and the 4D8C6 hybridoma in the amount of 170 ng (B). Unactivated wells were included as a negative control.
- the data shown in the graph express the absorbance at 450 nm emitted by the conversion of the substrate Tetramethylbenzidine to a colored compound catalyzed by the enzyme Horseradish peroxidase (HRP) present in the anti-L antibodies from the 2E11B5 and 4D8C6 hybridomas in the amount of 170 ng (A and B). Values correspond to the average +/- standard deviation of absorbance emitted by each sample in at least two independent experiments. ** P ⁇ 0.01 and *** P ⁇ 0.001 by the parametric student test comparing the results of the well called control (without sample) versus each of the dilutions of protein L.
- HRP horseradish peroxidase
- Figure 3 Assay of serial dilutions of the Flu anti-L monoclonal antibodies produced by the 2E11B5 and 4D8C6 hybridomas, for the detection of purified PIV antigens.
- ELISA plates were activated with 50 ng of recombinant PIV L protein and the antigen was detected with 11 serial dilutions 1: 2 of the anti-L antibodies 2E11B5 (A) or 4D8C6 (B), starting from a concentration of 3.4 mg / mL (170 ng per well).
- Data are expressed as the average +/- standard deviation of the absorbance value emitted at 450 nm for each sample in duplicate, in at least two independent experiments.
- Figure 4 Detection of PIV L protein, in infected cells, by monoclonal antibodies produced by hybridomas 2E11B5 and 4D8C6, by means of a Luminex assay.
- the plate was activated with 50 ng of purified recombinant PIV L protein, 20 pg of uninfected MDCK cells (used as a specificity control) and infected with PIV.
- the wells were incubated with anti-L antibodies from hybridoma 2E11B5 (conjugated to region 21 of PIV), in quantity of 50 microspheres / m ⁇ , which was used as capture antibody and the hybridoma 4D8C6 at a concentration of 4 mr / hIE used as detection antibody conjugated with biotin.
- FIG. 5 Detection of PIV in clinical samples by Sandwich ELISA and Sandwich type Luminex, using the combination of monoclonal antibodies secreted by hybridomas 2E11B5 and 4D8C6 for PIV.
- A) ELISA plates were activated with 170 ng of antibody secreted by the 2E11B5 hybridoma (anti-PIV), functioning as capture antibody.
- the wells activated with the capture antibodies for each virus were incubated with 50 m ⁇ of nasopharyngeal swab (HNF) samples from patients who had viral respiratory symptoms. As negative controls, 10 samples from healthy controls were analyzed.
- HNF nasopharyngeal swab
- Luminex plates were activated with 50 magnetic microspheres per m ⁇ , which were conjugated with the antibody secreted by the 2E11B5 hybridoma (anti-PIV), functioning as a capture antibody.
- the conjugated microspheres were incubated with 50 m ⁇ of nasopharyngeal swab (HNF) samples from patients presenting with viral respiratory symptoms. As negative controls, 8 samples from healthy controls were analyzed. Fourteen samples from PIV-positive patients were used and wells were added to the positive control to which was added purified L-PIV protein. For the detection of the protein captured by the 2E11B5 antibody, the antibodies produced by the 4D8C6 hybridoma, conjugated to the biotin fluorophore, were used at a concentration of 4 mg / mL.
- HNF nasopharyngeal swab
- the complex (microspheres conjugated with capture antibody, antigen and detection antibody) is incubated with Streptavidin / Phycoerythrin at a concentration 6 mg / mL.
- the data shows the median value of the absorbance emitted at 450 nm (A) or the MFI (B) of each sample (** P ⁇ 0.01 and **** p ⁇ 0.0001; using the student test nonparametric comparing PIV positive patients versus healthy controls, and against the viruses used as specificity control).
- Figure 6 Detection of L protein by indirect ELISA, using monoclonal antibodies secreted by biotin-conjugated 2E11B5 and 4D8C6 hybridomas.
- the figure shows a graph expressing the absorbance at 450 nm emitted by the conversion of the substrate
- Example 1 Determination of the nucleotide sequence encoding the light (VL) and heavy (VH) chains of the variable region of the anti-L PIV antibody secreted by the 2E11B5 hybridoma.
- the 2E11B5 hybridoma was grown in DMEM-high glucose culture medium supplemented with 3.7 g / L Sodium Bicarbonate and 10% fetal bovine serum, at 37 ° C with 10% CO2, up to a cell density of 700,000 cells / mL.
- the total RNA of 3.5 x 10 cells was obtained, carrying out a treatment with the compound Trizol (Invitrogen).
- RNA was used to generate the cDNA by reverse transcription reaction with the PrimeScriptTM lst Strand cDNA Synthesis Kit, which uses isotype specific universal cleavers.
- the light and heavy chain of the antibody were amplified according to the GenScript cDNA Extreme Rapid Amplification (RACE) Standard Operating Procedure (SOP). Amplified antibody fragments were cloned separately into a standard cloning vector. Colony PCR was performed to identify clones that had inserts of the correct size. At least five colonies with correct size inserts were sequenced for each fragment. The sequences of different clones were aligned and the consensus sequence of these clones was provided.
- the nucleotide sequences of the heavy and light chains of the antibodies secreted by the 2E11B5 hybridoma correspond to those identified as SEQ ID NO. one; SEQ ID NO .2 respectively.
- Example 2 Determination of the nucleotide sequence encoding the light (VL) and heavy (VH) chains of the variable region of the anti-L PIV antibody secreted by the 4D8C6 hybridoma.
- the 4D8C6 hybridoma was grown in DMEM-high glucose culture medium supplemented with 3.7 g / L Sodium Bicarbonate and 10% fetal bovine serum, at 37 ° C with 10% CO2, up to a cell density of 700,000 cells / mL.
- Total RNA of 3.5 was obtained xlO 6 cells, carrying out a treatment with the compound Trizol (Invitrogen).
- 0.5 pg of RNA was used to generate the cDNA by reverse transcription reaction with the PrimeScriptTM lst Strand cDNA Synthesis Kit, which uses isotype-specific universal cleavers.
- the light and heavy chain of the antibody were amplified according to the GenScript cDNA Extreme Rapid Amplification (RACE) Standard Operating Procedure (SOP).
- RACE GenScript cDNA Extreme Rapid Amplification
- SOP Standard Operating Procedure
- Amplified antibody fragments were cloned separately into a standard cloning vector. Colony PCR was performed to identify clones that had inserts of the correct size. At least five colonies with correct size inserts were sequenced for each fragment. The sequences of different clones were aligned and the consensus sequence of these clones was provided.
- the nucleotide sequences of the heavy and light chains of the antibodies secreted by the 4D8C6 hybridoma correspond to those identified as SEQ ID NO. 3; SEQ ID NO .4 respectively.
- Example 3 PIV Antigen Detection Assay, Determination of Specificity of PIV Anti-L Monoclonal Antibodies for Purified PIV Antigens by Indirect ELISA Assay.
- This assay aims to demonstrate the specificity for the PIV L protein of the antibodies produced by the 2E11B5 and 4D8C6 hybridomas.
- Antigen detection was carried out using the indirect ELISA technique, where the ELISA plate was activated with 50 ng of purified antigen for 1 hour at 37 ° C. In the same way, the plate was activated with 20 pg of E. col ⁇ bacterial strain strain BL21 without plasmid (used as a specificity control) and 3 clones (Cl, C2 and C3) of the same strain, in which it was over-expressed protein L. Other control Negative included was 50 ng of Flu2 PB2 protein in a separate well.
- the plate was washed twice with phosphate buffered saline (PBS) lX / Tween20 0.05%. The plate was then blocked for 2 hours at 37 ° C with PBS IX / 10% Fetal Bovine Serum (FBS). Subsequently, the washes were repeated and each of the antibodies (2E11B5 and 4D8C6) were then incubated at a final concentration of 3.4 pg / mL (170 ng per well), diluted in PBS 1X / 10% FBS, for 1 hour at 37 ° C (each antibody on a separate plate).
- PBS phosphate buffered saline
- FBS Fetal Bovine Serum
- Example 4 Assay to determine the sensitivity of monoclonal antibodies for detection of PIV anti-L viral antigens.
- the assay was performed to determine the maximum protein dilution that PIV anti-L monoclonal antibodies from 2E11B5 and 4D8C6 hybridomas are capable of detecting by indirect ELISA. For this, the same technique described in example 3 was used. The plate was activated with 11 serial dilutions 1: 2 of PIV protein L, starting with 50 ng of purified antigen. Anti-L antibodies 2E11B5 and 4D8C6 were used in a final concentration of 3.4 mr / hIE (170 ng / well), and were diluted in PBS 1X / 10% FBS.
- the anti-mouse IgG detection antibody was added in a dilution of 1: 2,000 (0.5 ng ⁇ L per well) and incubated for 1 hour at room temperature (25 ° C), in the dark.
- I know washes were performed and developed with 50 pL of citrate / tetramethylbenzidine buffer (TMB, 3-3 '-5- 5' tetramethylbenzidine, lmg / mL, Becton Dickinson).
- TMB citrate / tetramethylbenzidine buffer
- H2SO4 2N were added and the result was read in an ELISA reader, at 450nm.
- the anti-L 2E11B5 antibody is capable of detecting up to 390 picograms (pg) of the recombinant PIV L-chimera protein (Figure 2A).
- the anti-L antibody from the 4D8C6 hybridoma showed higher sensitivity than the anti-L 2E11B5 antibody ( Figure 2B), since it was able to detect up to 190 picograms of pure protein. Controls were included in all the tests that allowed to rule out nonspecific reactions of both the antibodies, which contained all components of the test except the sample (L PIV protein, data not shown in the graphs).
- Example 5 Assay to determine the efficiency of monoclonal antibodies to detect viral antigens of PIV, by indirect ELISA.
- the assay was performed to determine the maximum dilution of PIV anti-L monoclonal antibodies from 2E11B5 and 4D8C6 hybridomas, which allow detection of viral antigen.
- An ELISA plate was activated with 50 ng of purified antigen (L protein) and then the plate was blocked for 2 hours at 37 ° C with PBS IX / 10% Fetal Bovine Serum (FBS).
- the anti-L 2E11B5 and 4D8C6 antibodies were used in 1: 2 dilutions, starting from the working concentration (170 ng) up to the 11 dilution (0.15 ng) in PBS 1X / 10% FBS.
- the anti-mouse IgG detection antibody was added in a dilution of 1: 2,000 (0.5 ng / pL per well) and it was incubated 1 hour at room temperature (25 ° C), in the dark. Finally, the washes were carried out and it was developed with 50 pL of citrate / Tetramethylbenzidine buffer (TMB, 3- 3 '-5-5' tetramethylbenzidine, lmg / mL, Becton Dickinson). To stop the reaction, 50 m ⁇ of H2SO4 2N were added and the result was read in an ELISA reader, at 450nm.
- TMB citrate / Tetramethylbenzidine buffer
- both anti-L antibodies (2E11B5 and 4D8C6) can detect 50 ng of the purified antigen with high efficiency, since detection of the antigen with high signal was observed in all the dilutions carried out.
- the negative control included in this assay corresponds to a well that does not contain a sample (L protein), was blocked with PBS 1X / 10% FBS, primary antibody was added (anti-L 2E11B5 or anti-L 4D8C6) and also contains HRP-conjugated anti-mouse IgG antibody.
- Example 6 Detection of PIV L protein in cells infected with PIV, using monoclonal anti-L PIV antibodies, by means of the Sandwich Luminex technique.
- Luminex plates were activated with 50 magnetic microspheres by (internally marked with red or near-infrared fluorophore of different intensities) by mR, which were conjugated with the antibody secreted by the 2E11B5 hybridoma (anti-PIV), functioning as a capture antibody (at a final concentration of 2.5 mM).
- the conjugated microspheres were incubated with 50 mR of uninfected and PIV-infected MDCK cell, for 2 hours at room temperature ( «23 ° C), with stirring at 400 rpm and in the dark (covered with aluminum foil).
- As a negative control no sample was incubated in a well and as a positive control, 50 ng of L protein was used.
- the complex consisting of microspheres conjugated with capture antibody plus antigen and detection antibody, is incubated with 50 mE of Streptavidin / Fi-coeritrin at a final concentration of 6 mr / ihE. Incubation is carried out for 30 minutes at room temperature, in the dark, shaking at 400 rpm. Finally, two more washing steps are carried out and the wells are incubated with 100 mE of the Sheat fluid reagent (reagent used by the Luminex team for the team to read the samples), shake for 5 minutes at 400 rpm, in the dark.
- Sheat fluid reagent reagent used by the Luminex team for the team to read the samples
- Example 7 Clinical diagnosis of samples from patients infected with PIV, using PIV anti-L monoclonal antibodies, using the sandwich ELISA technique.
- a sandwich ELISA was performed, using the anti-L 2E11B5 antibody and the anti-L 4D8C6 as the detection antibody as capture antibody.
- PIV anti-L 4D8C6 detection antibody was conjugated to HRP.
- wells of an ELISA plate were activated with 3.4 mr / h ⁇ (170 ng / well) of the anti-L antibody from the PIV 2E11B5 hybridoma, diluted in PBS IX, for 1 hour at 37 ° C.
- the plate was then washed 2 more times, developed with 50m] 0 of TMB solution and incubated for 15 minutes in the dark.
- the reaction was stopped with 50 mB of H2SO4 2N and the plate was read at 450 nm in an ELISA reader (Epoch model), certified for clinical diagnosis.
- Figure 5A The results obtained for this assay are shown in Figure 5A, where it can be seen that the sandwich ELISA technique using the antibody (anti-L) from the 2E11B5 hybridoma, as the capture antibody and the antibody from the 4D8C6-HRP hybridoma As a detection antibody, it allows the antigen to be detected in samples from patients infected with PIV (Figure 5A), which were previously confirmed by direct immunofluorescence in a certified clinical laboratory using the viral panel.
- Figure 5A shows the results obtained with the anti-L antibodies to PIV, where 43 samples from patients diagnosed as positive PIV were used and as a control of specificity, 3 samples from patients positive for the Influenza virus were included. How Positive control included wells to which purified L-PIV protein was added.
- Example 8 Clinical diagnosis of samples from patients infected with PIV, using PIV anti-L monoclonal antibodies, using the Sandwich-type Luminex technique.
- Luminex plates were activated with 50 magnetic microspheres (internally marked with red or near-infrared fluorophore of different intensities) per mL, which were conjugated with the antibody secreted by the 2E11B5 hybridoma (anti-PIV), functioning as a capture antibody ( at a final concentration of 2.5 mM).
- the conjugated microspheres were incubated with 50 mL of nasopharyngeal swab (HNF) samples from patients presenting with viral respiratory conditions, for 2 hours at room temperature ("23 ° C), shaking at 400 rpm and in the dark (covered with tissue paper). aluminum) .
- HNF nasopharyngeal swab
- Incubation is carried out for 1 hour at room temperature, in the dark, shaking at 400 rpm. 2 washes are again performed with 100 mL 0.05% PBS lX-Tween20 for 30 seconds using the manual magnetic scrubber.
- the complex consisting of microspheres conjugated with capture antibody plus antigen and detection antibody, is incubated with 50 m] 0 of Streptavidin / Fi-coeritrin at a final concentration of 6 mr / pi. Incubation is carried out for 30 minutes at room temperature, in the dark, shaking at 400 rpm.
- FIG. 5B shows the results obtained for this assay.
- the Luminex technique like that obtained by the ELISA technique, using the antibody (anti-L) from the 2E11B5 hybridoma, as a Capture and the antibody from the 4D8C6-HRP hybridoma as a detection antibody, allows the antigen to be detected in samples from patients infected with PIV (Figure 5B) with high intensity, which were previously confirmed by direct immunofluorescence in a certified clinical laboratory using the panel viral.
- Figure 5B shows the results obtained with the anti-L antibodies to PIV, where 38 samples from patients diagnosed as positive PIV and 8 healthy control samples were used. In addition, wells to which purified L-PIV protein was added were used as a positive control. The results show that anti-PIV antibodies are specific in detecting only positive patients. for PIV and not the control subjects. All samples detected as positive by Luminex are those showing an MFI above two standard deviations from the average MFI of healthy controls.
- This assay demonstrates the versatility of antibodies from PIV 2E11B5 and 4D8C6 hybridomas, as they are capable of simultaneously binding to the antigen without competing for the binding site or interfere with each other and detect the low availability of the antigen in the nasopharyngeal swab sample.
- protein L which is a chimera protein, could be detected, which was constructed in the laboratory from three conserved fragments of the three most prevalent serotypes of human PIV (1, 2 and 3). .
- Example 9 Blind study for the detection of L-PIV antigen in clinical samples, obtained from patients carrying an infection, using monoclonal anti-L PIV antibodies, which are part of the multiple respiratory virus detection kit.
- sandwich ELISA tests were performed where the previous diagnosis of the samples to be evaluated was known. Subsequent to these trials, a blind study was performed, where nearly 150 samples of nasopharyngeal swabs were evaluated, without knowing the microbiological diagnosis.
- Sandwich ELISA were performed where anti-L 2E11B5 antibody and anti-L 4D8C6 were used as the capture antibody as HRP-conjugated detection antibody. For all the tests, wells of a plate were activated.
- FIG. 5A The results are shown in figure 5A, where the ability of the antibodies to detect protein L in clinical samples is observed, since they were designed from a chimera protein. 5 out of 7 positive IVP patients were detected, and from these results it was possible to determine the diagnostic accuracy of the antibodies, which is shown in Table 1.
- Table 1 The table shows the two concepts that define the diagnostic accuracy, where we have specificity, that is, the ability of antibodies to diagnose negative as negative samples, without detecting false positives, and on the other hand, we have sensitivity, that is, the ability of antibodies to diagnose as positive those samples that They really are, without diagnosing false negatives.
- Example 10 Detection of L protein by indirect ELISA assay, using monoclonal antibodies secreted by biotin-conjugated 2E11B5 and 4D8C6 hybridomas.
- ELISA plates were activated with 50 ⁇ m of 50 ng protein L and BSA. Specific sites blocked with 10% FBS diluted in PBS IX. 170 ng (3.4 pg / mL) of the Fab fragments of the antibodies secreted by the hybridomas 2E11B5 (anti-PIV) and 4D8C6 (anti-PIV), both previously conjugated biotin. Incubation of biotin-binding molecules (Streptavidin), which is conjugated with HRP (1: 2000 dilution, 75 ng per well) ( Figure 6, dark gray bar, 2E11B5 antibody and light gray bar, 4D8C6 antibody) .
- Example 10 PIV antigen detection assay, using F (ab ') 2 fragments of the anti-L monoclonal antibodies to PIV by indirect ELISA assay.
- the objective of this assay is to demonstrate the ability to detect fragments of anti-PIV antibodies, produced by hybridomas 2E11B5 and 4D8C6, by the protein chimera L.
- fragmentation of the IgG molecule from each anti PIV antibody Fragmentation was performed using the "Thermo Scientific TM F (ab ') 2 Pierce TM Fragment Preparation Kits" kit (# 10381214, Thermo Scientific), which separates the F (ab') 2 fragment and Fe from the of interest, by using the enzyme pepsin that digests the Fe fragment and subsequently purification steps are performed to separate the F (ab ') 2 fragment from the digested Fe fragment.
- F (ab ') 2 fraction was verified by the SDS-PAGE technique stained with coomassie blue.
- F (ab ') 2 fractions were conjugated to biotin molecules using the Lightning-Link rapid biotin type A rapid conjugation kit (# 370-0010, Expedeon). Having all the reagents ready, the detection of the antigen was carried out using the indirect ELISA technique, where the ELISA plate was activated with 50 ng of purified L antigen for 1 hour at 37 ° C. Two negative controls were included, one without a sample and the other incubating the well with 50 ng of BSA protein.
- the plate was washed twice with phosphate buffered saline (PBS) lX / Tween20 0.05%. The plate was then blocked for 2 hours at 37 ° C with PBS IX / 10% Fetal Bovine Serum (FBS). Subsequently, the washes were repeated and then each of the antibodies, unfractionated and biotin-conjugated F (ab ') 2 (2E11B5 and 4D8C6) fractions, were incubated at a final concentration of 3.4 pg / mL (170 ng per well ), diluted in 1X PBS / 10% FBS, for 1 hour at 37 ° C (each antibody on a separate plate).
- PBS phosphate buffered saline
- FBS Fetal Bovine Serum
- the washes were repeated and a biotin-binding protein (Streptavidin) labeled with the horseradish peroxidase enzyme (Horseradish peroxidase, HRP) in dilution 1 in 2000 (25 ng) was added to each well. / pL per well) in PBS 1X / FBS 10%, for 1 hour at room temperature (25 ° C), in the dark. Finally, the washes were performed and revealed with 50 pL of citrate / Tetramethylbenzidine buffer (TMB, 3-3 '-5-5' tetramethylbenzidine, lmg / mL, Becton Dickinson).
- TMB citrate / Tetramethylbenzidine buffer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3125208A CA3125208A1 (en) | 2018-12-28 | 2019-12-27 | Monoclonal antibody or antigen binding fragment thereof that binds to the l protein of the human parainfluenza virus (piv); method and kit for detecting piv |
CN201980093165.9A CN113490685A (zh) | 2018-12-28 | 2019-12-27 | 与人副流感病毒(piv)的l蛋白相结合的单克隆抗体或其抗原结合部分;用于检测piv病毒的方法和试剂盒 |
MX2021007870A MX2021007870A (es) | 2018-12-28 | 2019-12-27 | Anticuerpos monoclonales especificos para la proteina quimerica l del virus de la parainfluenza humana (piv), secuencias nucleotidicas; metodo y kit de diagnostico de infeccion producida por piv. |
BR112021012788A BR112021012788A2 (pt) | 2018-12-28 | 2019-12-27 | Anticorpo monoclonal ou uma porção de união a antígeno do mesmo que se une à proteína l do vírus parainfluenza humano (piv), método e kit para detectar o vírus piv |
PE2021001089A PE20212104A1 (es) | 2018-12-28 | 2019-12-27 | Anticuerpos monoclonales especificos para la proteina quimerica l del virus de la parainfluenza humana (piv), secuencias nucleotidicas, metodo y kit de diagnostico de infeccion producida por piv |
EP19903462.0A EP3904379A4 (en) | 2018-12-28 | 2019-12-27 | HUMAN PARAINFLUENCE VIRUS (PIV) L-PROTEIN BINDING MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHODS AND KIT FOR THE DETECTION OF PIV |
KR1020217024084A KR20210110660A (ko) | 2018-12-28 | 2019-12-27 | 인간 파라인플루엔자 바이러스(piv)의 l 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편, piv 검출을 위한 방법 및 키트 |
US17/418,617 US20220089697A1 (en) | 2018-12-28 | 2019-12-27 | Monoclonal antibody or antigen binding fragment thereof that binds to the l protein of the human parainfluenza virus (piv); method and kit for detecting piv |
CONC2021/0008770A CO2021008770A2 (es) | 2018-12-28 | 2021-07-01 | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv |
ZA2021/04990A ZA202104990B (en) | 2018-12-28 | 2021-07-15 | Monoclonal antibody or antigen binding fragment thereof that binds to the l protein of the human parainfluenza virus (piv); method and kit for detecting piv |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL3869-2018 | 2018-12-28 | ||
CL2018003869A CL2018003869A1 (es) | 2018-12-28 | 2018-12-28 | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020132774A1 true WO2020132774A1 (es) | 2020-07-02 |
Family
ID=71125643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CL2019/050157 WO2020132774A1 (es) | 2018-12-28 | 2019-12-27 | Anticuerpo monoclonal o una porción de unión a antígeno del mismo que se une a la proteína l del virus parainfluenza humano (piv); método y kit para detectar al virus piv |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220089697A1 (es) |
EP (1) | EP3904379A4 (es) |
KR (1) | KR20210110660A (es) |
CN (1) | CN113490685A (es) |
AR (1) | AR117548A1 (es) |
BR (1) | BR112021012788A2 (es) |
CA (1) | CA3125208A1 (es) |
CL (1) | CL2018003869A1 (es) |
CO (1) | CO2021008770A2 (es) |
MX (1) | MX2021007870A (es) |
PE (1) | PE20212104A1 (es) |
UY (1) | UY38534A (es) |
WO (1) | WO2020132774A1 (es) |
ZA (1) | ZA202104990B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113736920A (zh) * | 2021-09-15 | 2021-12-03 | 丹娜(天津)生物科技股份有限公司 | 一种九项呼吸道病原体分子检测试剂盒及其使用方法和应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015664A (en) | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
AU2003256823B9 (en) * | 2002-07-25 | 2009-01-08 | Medimmune, Llc | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
US20110076268A1 (en) * | 2009-08-13 | 2011-03-31 | Robert Anthony Williamson | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
CN102140550A (zh) | 2011-03-25 | 2011-08-03 | 武汉大学 | 副流感病毒一步rt-pcr检测试剂盒 |
US20130177573A1 (en) * | 2010-07-09 | 2013-07-11 | Robert Anthony Williamson | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
WO2013112720A1 (en) * | 2012-01-24 | 2013-08-01 | University Of Georgia Research Foundation, Inc. | Parainfluenza virus 5 based vaccines |
CN105441589A (zh) | 2015-12-21 | 2016-03-30 | 深圳市生科源技术有限公司 | 人副流感病毒ⅰ、ⅱ、ⅲ、ⅳ型四重pcr检测试剂盒及其检测方法 |
WO2017021815A2 (en) * | 2015-07-31 | 2017-02-09 | Pontificia Universidad Católica De Chile | Monoclonal antibodies specifically for the antigen p of the human respiratory syncytial virus, produced and secreted by the cells hybridomas, useful for detection and diagnostic of the infection caused by rsv |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100233674A1 (en) * | 2002-04-25 | 2010-09-16 | University Hospitals Of Cleveland | Cells for detection and production of influenza and parainfluenza viruses |
US8492097B2 (en) * | 2006-04-24 | 2013-07-23 | Diagnostic Hybrids, Inc. | Compositions and methods for human metapneumovirus monoclonal antibodies |
US8003314B2 (en) * | 2007-04-16 | 2011-08-23 | Diagnostic Hybrids, Inc. | Methods for direct fluorescent antibody virus detection in liquids |
CL2016000164A1 (es) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv. |
-
2018
- 2018-12-28 CL CL2018003869A patent/CL2018003869A1/es unknown
-
2019
- 2019-12-27 CA CA3125208A patent/CA3125208A1/en active Pending
- 2019-12-27 MX MX2021007870A patent/MX2021007870A/es unknown
- 2019-12-27 AR ARP190103908A patent/AR117548A1/es unknown
- 2019-12-27 KR KR1020217024084A patent/KR20210110660A/ko active Search and Examination
- 2019-12-27 BR BR112021012788A patent/BR112021012788A2/pt unknown
- 2019-12-27 US US17/418,617 patent/US20220089697A1/en active Pending
- 2019-12-27 EP EP19903462.0A patent/EP3904379A4/en active Pending
- 2019-12-27 CN CN201980093165.9A patent/CN113490685A/zh active Pending
- 2019-12-27 UY UY0001038534A patent/UY38534A/es unknown
- 2019-12-27 WO PCT/CL2019/050157 patent/WO2020132774A1/es unknown
- 2019-12-27 PE PE2021001089A patent/PE20212104A1/es unknown
-
2021
- 2021-07-01 CO CONC2021/0008770A patent/CO2021008770A2/es unknown
- 2021-07-15 ZA ZA2021/04990A patent/ZA202104990B/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015664A (en) | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
US20100278813A1 (en) * | 2001-01-19 | 2010-11-04 | Medimmune, Inc. | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
AU2003256823B9 (en) * | 2002-07-25 | 2009-01-08 | Medimmune, Llc | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
US20110076268A1 (en) * | 2009-08-13 | 2011-03-31 | Robert Anthony Williamson | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
US20130177573A1 (en) * | 2010-07-09 | 2013-07-11 | Robert Anthony Williamson | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
CN102140550A (zh) | 2011-03-25 | 2011-08-03 | 武汉大学 | 副流感病毒一步rt-pcr检测试剂盒 |
WO2013112720A1 (en) * | 2012-01-24 | 2013-08-01 | University Of Georgia Research Foundation, Inc. | Parainfluenza virus 5 based vaccines |
WO2017021815A2 (en) * | 2015-07-31 | 2017-02-09 | Pontificia Universidad Católica De Chile | Monoclonal antibodies specifically for the antigen p of the human respiratory syncytial virus, produced and secreted by the cells hybridomas, useful for detection and diagnostic of the infection caused by rsv |
CN105441589A (zh) | 2015-12-21 | 2016-03-30 | 深圳市生科源技术有限公司 | 人副流感病毒ⅰ、ⅱ、ⅲ、ⅳ型四重pcr检测试剂盒及其检测方法 |
Non-Patent Citations (8)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113736920A (zh) * | 2021-09-15 | 2021-12-03 | 丹娜(天津)生物科技股份有限公司 | 一种九项呼吸道病原体分子检测试剂盒及其使用方法和应用 |
CN113736920B (zh) * | 2021-09-15 | 2023-09-01 | 丹娜(天津)生物科技股份有限公司 | 一种九项呼吸道病原体分子检测试剂盒及其使用方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
ZA202104990B (en) | 2023-01-25 |
CA3125208A1 (en) | 2020-07-02 |
BR112021012788A2 (pt) | 2021-11-16 |
MX2021007870A (es) | 2021-12-10 |
EP3904379A4 (en) | 2022-08-17 |
EP3904379A1 (en) | 2021-11-03 |
PE20212104A1 (es) | 2021-11-04 |
CO2021008770A2 (es) | 2021-07-19 |
CL2018003869A1 (es) | 2021-01-15 |
CN113490685A (zh) | 2021-10-08 |
AR117548A1 (es) | 2021-08-11 |
UY38534A (es) | 2020-07-31 |
US20220089697A1 (en) | 2022-03-24 |
KR20210110660A (ko) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2784888T3 (es) | Anticuerpo monoclonal específico para la proteína P del Virus Respiratorio Sincicial humano y uso del mismo para la detección y diagnóstico de infección por VRS | |
WO2021169664A1 (zh) | 新型冠状病毒抗原及其检测用途 | |
US9273122B2 (en) | Monoclonal antibodies specific for the M2-1 antigen of respiratory syncytial virus (RSV) | |
ES2898068T3 (es) | Anticuerpos monoclonales específicos para el antígeno pIII de Adenovirus humano (ADV), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por ADV | |
WO2020132774A1 (es) | Anticuerpo monoclonal o una porción de unión a antígeno del mismo que se une a la proteína l del virus parainfluenza humano (piv); método y kit para detectar al virus piv | |
WO2020132772A1 (es) | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu | |
US9995747B2 (en) | Specific monoclonal antibodies of the antigen M of the human metapneumovirus (HMPV) and use thereof in a diagnostic method | |
WO2020047683A1 (es) | Anticuerpo monoclonal específico contra el antígeno n del virus respiratorio sincicial humano (vrsh), útiles para el tratamiento de la infección, su detección y diagnóstico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19903462 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3125208 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021012788 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20217024084 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019903462 Country of ref document: EP Effective date: 20210728 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112021012788 Country of ref document: BR Free format text: APRESENTE O COMPLEMENTO DO TEXTO EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDOCONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO E DESENHO, SE HOUVER), CONFORMEDETERMINA A RESOLUCAO INPI PR NO 77/2013 DE 18/03/2013, ART. 5O E 7O. |
|
ENP | Entry into the national phase |
Ref document number: 112021012788 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210628 |